Karuna Therapeutics, Inc. (KRTX): Price and Financial Metrics

Karuna Therapeutics, Inc. (KRTX): $329.83

0.09 (+0.03%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

D

Add KRTX to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#314 of 342

in industry

KRTX Price/Volume Stats

Current price $329.83 52-week high $329.99
Prev. close $329.74 52-week low $158.38
Day low $329.75 Volume 1,868,500
Day high $329.99 Avg. volume 832,048
50-day MA $317.38 Dividend yield N/A
200-day MA $228.31 Market Cap 12.58B

KRTX Stock Price Chart Interactive Chart >


Karuna Therapeutics, Inc. (KRTX) Company Bio


Karuna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It engages in business of research and development of therapies utilizing muscarinic cholinergic receptors to treat psychosis and cognitive impairment in numerous central nervous system disorders. The company develops treatments for people afflicted with schizophrenia. Karuna Therapeutics was founded in July 2009 by Andrew Miller, Eric Elenko and Peter Jeffrey Conn and is headquartered in Boston, MA.


KRTX Latest News Stream


Event/Time News Detail
Loading, please wait...

KRTX Latest Social Stream


Loading social stream, please wait...

View Full KRTX Social Stream

Latest KRTX News From Around the Web

Below are the latest news stories about KARUNA THERAPEUTICS INC that investors may wish to consider to help them evaluate KRTX as an investment opportunity.

Biotech Stock Roundup: BMY's KRTX and RYZB Acquisition, CYTK Surges on Study Data

Bristol Myers (BMY) and Cytokinetics (CYTK) are in the news on acquisition announcements and study updates, respectively.

Yahoo | December 28, 2023

Bristol Myers (BMY) to Buy Cancer Drug-Maker RayzeBio for $4.1B

Bristol Myers (BMY) is set to acquire RayzeBio for $4.1 billion to strengthen and diversify its already established oncology portfolio. The transaction is expected to close in the first half of 2024.

Yahoo | December 27, 2023

Trending tickers: Intel | Tencent | RayzeBio | Astrazeneca

The latest investor updates on stocks that are trending on Wednesday.

Yahoo | December 27, 2023

Why Is RayzeBio (RYZB) Stock Up 100% Today?

RYZB stock has doubled today after Bristol Myers Squibb shelled out $4.1 billion to buy RayzeBio.

Dana Blankenhorn on InvestorPlace | December 26, 2023

Bristol Myers buying RayzeBio, FedEx buyback: Trending tickers

FedEx (FDX) shares rose after the shipping giant announced a $1 billion accelerated share buyback plan. Shares of RayzeBio (RYZB) jumped 100% after it was announced the company was being acquired by Bristol Myers Squibb (BMY) in a $4.1 billion deal. It's Bristol Myers' second deal in less than a week. On Friday, the company announced it was acquiring Karuna Therapeutics (KRTX) in a $14 billion deal. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live.

Yahoo | December 26, 2023

Read More 'KRTX' Stories Here

KRTX Price Returns

1-mo N/A
3-mo N/A
6-mo 4.05%
1-year 45.11%
3-year 159.06%
5-year N/A
YTD 4.21%
2023 61.07%
2022 50.00%
2021 28.95%
2020 34.84%
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!